These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 21854272)

  • 1. Gender research in the National Institute on Drug Abuse National Treatment Clinical Trials Network: a summary of findings.
    Greenfield SF; Rosa C; Putnins SI; Green CA; Brooks AJ; Calsyn DA; Cohen LR; Erickson S; Gordon SM; Haynes L; Killeen T; Miele G; Tross S; Winhusen T
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):301-12. PubMed ID: 21854272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NIDA's Clinical Trials Network: an opportunity for HIV research in community substance abuse treatment programs.
    Tross S; Campbell AN; Calsyn DA; Metsch LR; Sorensen JL; Shoptaw S; Haynes L; Woody GE; Malow RM; Brown LS; Feaster DJ; Booth RE; Mandler RN; Masson C; Holmes BW; Colfax G; Brooks AJ; Hien DA; Schackman BR; Korthuis PT; Miele GM;
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):283-93. PubMed ID: 21854270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality assurance of research protocols conducted in the community: the National Institute on Drug Abuse Clinical Trials Network experience.
    Rosa C; Campbell A; Kleppinger C; Sampson R; Tyson C; Mamay-Gentilin S
    Clin Trials; 2009 Apr; 6(2):151-61. PubMed ID: 19342468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between Clinical Trial Network protocol involvement and quality of substance use disorder treatment.
    Abraham AJ; Knudsen HK; Roman PM
    J Subst Abuse Treat; 2014 Feb; 46(2):232-7. PubMed ID: 24080073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The application of digital health to the assessment and treatment of substance use disorders: The past, current, and future role of the National Drug Abuse Treatment Clinical Trials Network.
    Marsch LA; Campbell A; Campbell C; Chen CH; Ertin E; Ghitza U; Lambert-Harris C; Hassanpour S; Holtyn AF; Hser YI; Jacobs P; Klausner JD; Lemley S; Kotz D; Meier A; McLeman B; McNeely J; Mishra V; Mooney L; Nunes E; Stafylis C; Stanger C; Saunders E; Subramaniam G; Young S
    J Subst Abuse Treat; 2020 Mar; 112S():4-11. PubMed ID: 32220409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: have we chosen the best designs?
    Nunes EV; Ball S; Booth R; Brigham G; Calsyn DA; Carroll K; Feaster DJ; Hien D; Hubbard RL; Ling W; Petry NM; Rotrosen J; Selzer J; Stitzer M; Tross S; Wakim P; Winhusen T; Woody G
    J Subst Abuse Treat; 2010 Jun; 38 Suppl 1(Suppl 1):S97-112. PubMed ID: 20307801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maximizing Effectiveness Trials in PTSD and SUD Through Secondary Analysis: Benefits and Limitations Using the National Institute on Drug Abuse Clinical Trials Network "Women and Trauma" Study as a Case Example.
    Hien DA; Campbell AN; Ruglass LM; Saavedra L; Mathews AG; Kiriakos G; Morgan-Lopez A
    J Subst Abuse Treat; 2015 Sep; 56():23-33. PubMed ID: 25907849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: an example from the NIDA Clinical Trials Network.
    Campbell AN; Nunes EV; Miele GM; Matthews A; Polsky D; Ghitza UE; Turrigiano E; Bailey GL; VanVeldhuisen P; Chapdelaine R; Froias A; Stitzer ML; Carroll KM; Winhusen T; Clingerman S; Perez L; McClure E; Goldman B; Crowell AR
    Contemp Clin Trials; 2012 Mar; 33(2):386-95. PubMed ID: 22085803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The first decade of the National Drug Abuse Treatment Clinical Trials Network: bridging the gap between research and practice to improve drug abuse treatment.
    Tai B; Straus MM; Liu D; Sparenborg S; Jackson R; McCarty D
    J Subst Abuse Treat; 2010 Jun; 38 Suppl 1(Suppl 1):S4-13. PubMed ID: 20307794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How practice and science are balanced and blended in the NIDA Clinical Trials Network: the bidirectional process in the development of the STAGE-12 protocol as an example.
    Donovan DM; Daley DC; Brigham GS; Hodgkins CC; Perl HI; Floyd AS
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):408-16. PubMed ID: 21854284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic scoping review of research on Black participants in the National Drug Abuse Treatment Clinical Trials Network.
    Montgomery L; Burlew AK; Haeny AM; Jones CA
    Psychol Addict Behav; 2020 Feb; 34(1):117-127. PubMed ID: 31246072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality Rates Among Substance Use Disorder Participants in Clinical Trials: Pooled Analysis of Twenty-Two Clinical Trials Within the National Drug Abuse Treatment Clinical Trials Network.
    Lindblad R; Hu L; Oden N; Wakim P; Rosa C; VanVeldhuisen P
    J Subst Abuse Treat; 2016 Nov; 70():73-80. PubMed ID: 27692192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study results from the Clinical Trials Network's first 10 years: where do they lead?
    Wells EA; Saxon AJ; Calsyn DA; Jackson TR; Donovan DM
    J Subst Abuse Treat; 2010 Jun; 38 Suppl 1(Suppl 1):S14-30. PubMed ID: 20307792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors and moderators of outcomes of HIV/STD sex risk reduction interventions in substance abuse treatment programs: a pooled analysis of two randomized controlled trials.
    Crits-Christoph P; Gallop R; Sadicario JS; Markell HM; Calsyn DA; Tang W; He H; Tu X; Woody G
    Subst Abuse Treat Prev Policy; 2014 Jan; 9():3. PubMed ID: 24433412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site selection in community-based clinical trials for substance use disorders: strategies for effective site selection.
    Potter JS; Donovan DM; Weiss RD; Gardin J; Lindblad R; Wakim P; Dodd D
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):400-7. PubMed ID: 21854283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten take home lessons from the first 10 years of the CTN and 10 recommendations for the future.
    Carroll KM; Ball SA; Jackson R; Martino S; Petry NM; Stitzer ML; Wells EA; Weiss RD
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):275-82. PubMed ID: 21854269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing ethnic minority participation in substance abuse clinical trials: lessons learned in the National Institute on Drug Abuse's Clinical Trials Network.
    Burlew K; Larios S; Suarez-Morales L; Holmes B; Venner K; Chavez R
    Cultur Divers Ethnic Minor Psychol; 2011 Oct; 17(4):345-56. PubMed ID: 21988575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standardized patient walkthroughs in the National Drug Abuse Treatment Clinical Trials Network: common challenges to protocol implementation.
    Fussell HE; Kunkel LE; McCarty D; Lewy CS
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):434-9. PubMed ID: 21854287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender differences in the rates and correlates of HIV risk behaviors among drug abusers.
    Brooks A; Meade CS; Potter JS; Lokhnygina Y; Calsyn DA; Greenfield SF
    Subst Use Misuse; 2010 Dec; 45(14):2444-69. PubMed ID: 20536356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.